TR200100588T2 - Hücre yapışmasının önlenmesini modüle eden aza-bisikleler. - Google Patents

Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.

Info

Publication number
TR200100588T2
TR200100588T2 TR2001/00588T TR200100588T TR200100588T2 TR 200100588 T2 TR200100588 T2 TR 200100588T2 TR 2001/00588 T TR2001/00588 T TR 2001/00588T TR 200100588 T TR200100588 T TR 200100588T TR 200100588 T2 TR200100588 T2 TR 200100588T2
Authority
TR
Turkey
Prior art keywords
aza
bicycles
cell adhesion
adhesion prevention
modulate cell
Prior art date
Application number
TR2001/00588T
Other languages
English (en)
Inventor
Bourzat Jean-Dominique
Commercon Alain
Jacques Christophe Filoche Bruno
Victor Harris Neil
Mccarthy Clive
Pharma Limited Aventis
Original Assignee
Pharma Limited Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9818641.4A external-priority patent/GB9818641D0/en
Application filed by Pharma Limited Aventis filed Critical Pharma Limited Aventis
Publication of TR200100588T2 publication Critical patent/TR200100588T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electroluminescent Light Sources (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Secondary Cells (AREA)

Abstract

Bulus, temsil ettigi formül (I)'e ait fizyolojik açidan aktif bilesiklerle; ve ilgili N-oksitlerle; ve bu bilesiklerin ve bunlarin N-oksitlerinin ve ön ilaçlarinin farmasötik açidan kabul gören tuzlari ve solvatlariyla ilgilidir. Bu bilesikler, degerli farmasötik özellikler gösterirler, özellikle de VCAM-1 ve fibronektinin VLA-4 (alfa4 1) integrini ile etkilesimini düzenleyebilirler. (FORMÜL VAR)
TR2001/00588T 1998-08-26 1999-08-26 Hücre yapışmasının önlenmesini modüle eden aza-bisikleler. TR200100588T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818641.4A GB9818641D0 (en) 1998-08-26 1998-08-26 Chemical compounds
US11000898P 1998-11-25 1998-11-25

Publications (1)

Publication Number Publication Date
TR200100588T2 true TR200100588T2 (tr) 2001-08-21

Family

ID=26314269

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00588T TR200100588T2 (tr) 1998-08-26 1999-08-26 Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.

Country Status (21)

Country Link
US (1) US6608084B1 (tr)
EP (1) EP1114028B1 (tr)
KR (1) KR20010085630A (tr)
CN (1) CN1323295A (tr)
AT (1) ATE346841T1 (tr)
AU (1) AU754557B2 (tr)
BR (1) BR9913222A (tr)
CA (1) CA2341677A1 (tr)
DE (1) DE69934238T2 (tr)
DK (1) DK1114028T3 (tr)
ES (1) ES2276530T3 (tr)
HU (1) HUP0104766A3 (tr)
IL (2) IL141596A0 (tr)
MX (1) MXPA01001995A (tr)
NO (1) NO20010942L (tr)
NZ (1) NZ509781A (tr)
PL (1) PL346248A1 (tr)
PT (1) PT1114028E (tr)
SK (1) SK2612001A3 (tr)
TR (1) TR200100588T2 (tr)
WO (1) WO2000015612A1 (tr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177186B1 (en) * 1999-05-05 2004-03-31 Aventis Pharma Limited Ureas and their use as cell adhesion modulators
NZ518886A (en) 1999-12-28 2004-02-27 Pfizer Prod Inc Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001235806A1 (en) * 2000-03-01 2001-09-12 Aventis Pharma Limited 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
MXPA03003829A (es) 2000-11-04 2003-07-28 Aventis Pharma Ltd Acidos alcanoicos substituidos.
TWI312779B (tr) 2000-12-28 2009-08-01 Daiichi Seiyaku Co
ES2296926T3 (es) * 2001-06-06 2008-05-01 Aventis Pharma Limited Tetrahidroisoquinolinas sustituidas para usar en el tratamiento de enfermedades inflamatorias.
WO2003011815A1 (en) * 2001-07-26 2003-02-13 Celltech R & D Limited Bicyclic heteroaromatic alanines
WO2003093237A1 (en) 2002-04-30 2003-11-13 Ucb, S.A. 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors
OA13038A (en) 2003-03-12 2006-11-10 Pfizer Prod Inc Pryridyloxymethyl and benzisoxazole azabicyclic derivatives.
MXPA06000850A (es) 2003-07-24 2006-03-30 Daiichi Seiyaku Co Compuesto de acido ciclohexancarboxilico.
JP2008542407A (ja) 2005-06-09 2008-11-27 ユセベ ファルマ ソシエテ アノニム ２，６キノリニル誘導体、それらを調製するための方法及び薬剤としてのそれらの使用
US7741317B2 (en) * 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
JP2009516730A (ja) * 2005-11-23 2009-04-23 アストラゼネカ アクチボラグ Ｌ−アラニン誘導体
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
WO2010151711A1 (en) * 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
WO2011084851A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Asenapine produrugs
US9107911B2 (en) 2010-01-07 2015-08-18 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
US20110166156A1 (en) * 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
WO2011084849A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders
WO2011084846A1 (en) 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
ES2691671T3 (es) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8894846B2 (en) * 2010-12-23 2014-11-25 Stephen Lee Yarbro Using supercritical fluids to refine hydrocarbons
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CA2858787C (en) 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
US9193685B2 (en) 2012-09-19 2015-11-24 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
SG11201604795RA (en) 2013-12-20 2016-07-28 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1497118A1 (de) * 1965-05-29 1969-04-17 Agfa Gevaert Ag Sensibilisierte elektrophotographische Schichten
ATE9329T1 (de) * 1980-06-18 1984-09-15 May & Baker Limited Indol- und indolin-derivate.
DE68920147T2 (de) * 1989-10-12 1995-06-29 Ibm Anzeigesystem.
AU693143B2 (en) * 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1998007716A2 (en) * 1996-08-23 1998-02-26 The Board Of Regents For Oklahoma State University Heteroarotinoids-anticancer agents with receptor specificity and tgase activity
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten

Also Published As

Publication number Publication date
SK2612001A3 (en) 2001-11-06
AU5634399A (en) 2000-04-03
EP1114028B1 (en) 2006-11-29
KR20010085630A (ko) 2001-09-07
PT1114028E (pt) 2007-02-28
NZ509781A (en) 2003-05-30
IL141596A (en) 2006-07-05
US6608084B1 (en) 2003-08-19
CA2341677A1 (en) 2000-03-23
CN1323295A (zh) 2001-11-21
NO20010942L (no) 2001-04-19
AU754557B2 (en) 2002-11-21
MXPA01001995A (es) 2004-07-30
DE69934238D1 (de) 2007-01-11
DK1114028T3 (da) 2007-04-30
HUP0104766A2 (hu) 2002-04-29
WO2000015612A1 (en) 2000-03-23
PL346248A1 (en) 2002-01-28
IL141596A0 (en) 2002-03-10
ATE346841T1 (de) 2006-12-15
ES2276530T3 (es) 2007-06-16
HUP0104766A3 (en) 2002-08-28
EP1114028A1 (en) 2001-07-11
DE69934238T2 (de) 2007-06-21
BR9913222A (pt) 2001-10-16
NO20010942D0 (no) 2001-02-23

Similar Documents

Publication Publication Date Title
TR200100588T2 (tr) Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
DK1027328T3 (da) Substituerede anilider
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
MY115662A (en) Novel compounds with analgesic effect
BG106586A (en) Pyrazolopyramidines as therapeutic agents
TR200101124T2 (tr) N-(2-aril-propiyonil)-sülfonamidler ve bunları içeren farmasötik preparasyonlar.
ES2181853T3 (es) Tratamiento del tinnitus empleando agentes neuroprotectores.
HUT74431A (en) Pharmaceutical composition to the blocking the accumulation of germs on human cells
TR200001947T2 (tr) İkame edilmiş B-Alaninler.
SE9504662D0 (sv) New compounds
TR200100059T2 (tr) Yeni antimikrobik bileşimler
ES2108298T3 (es) 4-estrenos puenteados en 19,11, activos como gestagenos.
WO2001046178A3 (en) Substituierte bisindolymaleimide
IT1273455B (it) Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
TR200100354T2 (tr) NK-2 Antagonist hareketine sahip monosiklik bileşimler ve oluşumlar.
DE69634387D1 (de) Mercapto derivate mit metallopeptidase(ace/nep) inhibiernder wirkung
PE61999A1 (es) Compuestos de tetrahidropiridina